Artigo

Aspirin in primary prevention and the risk of heart failure: a systematic review and meta-analysis of controlled trials

CARISI ANNE POLANCZYK

ESC HEART FAILURE, v. 10, n. 0, p. 1488-1491, 2022.

Motivo: Produção Corpo Clínico

Setor HMV: Clínica Médica

Área da saúde: Cardiologia

Resumo: The prevalence of heart failure (HF) worldwide nearly doubled from 33.5 million in 1990 to 64.3 million in 2017.1 Although the age-standardized prevalence rate of HF has decreased by 20.3% in high-income countries, it remained stable or increased in middle-income countries (MIC) such as countries like India and China. Although the increased burden of obesity, diabetes and hypertension may justify this epidemiological scenario in MIC,2 a similar increase in these cardiometabolic factors does not seem sufficient to influence trends in high-income countries. Exploring novel risk factors for HF in primary prevention setting may reveal new targets for policymakers. Mujaj et al.3 reported a cohort-designed primary prevention (PP)-based large-scale study and showed a 26% increase in the risk of incident HF among aspirin users compared to non-users. The authors did both multivariate and propensity score-adjusted analyses to control for confounding factors, and pointed out for similar results.

Envie um e-mail para os autores